HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Porphyria Cutanea Tarda

An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.
Networked: 780 relevant articles (31 outcomes, 37 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Porphyrias
2. Erythropoietic Protoporphyria
3. Iron Overload
4. Infection
5. Urticaria (Hives)

Experts

1. Phillips, J D: 7 articles (04/2009 - 11/2000)
2. Bonkovsky, Herbert L: 6 articles (01/2013 - 04/2002)
3. Kushner, J P: 6 articles (01/2009 - 11/2000)
4. Anderson, Karl E: 5 articles (12/2012 - 02/2002)
5. Stölzel, U: 5 articles (12/2010 - 11/2000)
6. Herrero, Carmen: 5 articles (11/2010 - 02/2002)
7. Frank, Jorge: 5 articles (10/2010 - 06/2004)
8. Gorman, Nadia: 5 articles (12/2007 - 04/2002)
9. Sinclair, Jacqueline F: 5 articles (12/2007 - 04/2002)
10. Sinclair, Peter R: 5 articles (12/2007 - 04/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Porphyria Cutanea Tarda:
1. Chloroquine (Aralen)FDA LinkGeneric
2. IronIBA
3. Hydroxychloroquine (Plaquenil)FDA LinkGeneric
4. Cimetidine (Biomet)FDA LinkGeneric
5. Uroporphyrinogen Decarboxylase (Uroporphyrinogen III Decarboxylase)IBA
6. PorphyrinsIBA
7. anastrozole (Arimidex)FDA LinkGeneric
8. Deferoxamine (Desferal)FDA LinkGeneric
9. Glutathione (Reduced Glutathione)IBA
10. InterferonsIBA

Therapies and Procedures

1. Renal Dialysis (Hemodialysis)
2. Amputation
3. Blood Transfusion (Blood Transfusions)
4. Transplants (Transplant)
5. Aftercare (After-Treatment)